Navigation Links
The Quigley Corporation Reports First Quarter 2009 Results
Date:5/1/2009

loping natural-source potential prescription and other products. Research and development costs associated with Quigley Pharma for the first quarter of 2009 were $248,000 compared to $1.4 million for the first quarter of 2008. This reduction reflects the completion of the Phase IIb clinical study for QR-333 Diabetic Peripheral Neuropathy in November 2008, which reduced R&D investment costs for the first quarter of 2009.

On April 30, 2009, the Company announced that its Diabetic Peripheral Neuropathy Phase IIb clinical study demonstrated a significant improvement in two key measures of distal sensory nerve function in the group treated with QR-333. These unexpected positive findings expand the potential for the QR-333 drug for Diabetic Neuropathy and suggest possible disease modification.

No tax provision or benefits to reduce losses are provided for the first quarter of 2009 and 2008, as the Company is in a net operating loss carry-forward position for which a valuation has been established.

The Company continued to invest in pharmaceutical research and development including QR448(a), a veterinary anti-viral compound against Infectious Bronchitis Virus (IBV) in poultry, and QR-333, an investigational new formulation for treating conditions associated with Diabetic Peripheral Neuropathy.

The research by the Company is part of its strategic initiatives to generate future growth. These initiatives include capitalizing on the growth potential of Quigley Pharma by developing natural-source potential prescription products particularly for Diabetic Peripheral Neuropathy, avian flu in animals and for protection against ionizing radiation.

Ongoing Quigley Pharma research and development initiatives include investing in its key pharmaceutical formulations, QR-333. The last subject in the Phase IIb study completed treatment at the end November 2008 and the study is now in the final
'/>"/>

SOURCE The Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification
2. The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future
3. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
4. The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical R&D Future
5. The Quigley Corporation Names Gerard M. Gleeson to Succeed Retiring George J. Longo as Chief Financial Officer and Director
6. The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future
7. The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007
8. The Quigley Corporation Announces Sale of Its Health and Wellness Segment
9. Providence Service Corporation to Report First Quarter 2009 Results on Wednesday, May 6th After the Market Closes
10. Protein Sciences Corporation Appoints New Board of Directors
11. Digirad Corporation Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 Don’t have time to go ... fitness membership? Don’t know which workout equipment to use? ... order to help members achieve their heath and fitness ... an educational, caused-based wellness company, today announces the launch ... classes led by certified trainers, nutritional information and recipes ...
(Date:5/5/2015)... May 05, 2015 Major League Ultimate ... the belief that ultimate Frisbee™ is home to many ... sport that engages the world. Nike Ultimate Camps’ goal ... creating opportunities for young athletes to learn about the ... MLU the perfect fit. , The Nike Ultimate Camp ...
(Date:5/5/2015)... 05, 2015 Igantia , an ... leads an international initiative to examine key biological milestones ... human lifespan. Scientists at Igantia believe that better ... the initiation of her menstrual cycle to her transition ... aging and, ultimately, extend the lifespan. , By ...
(Date:5/5/2015)... St.Louis MO (PRWEB) May 05, 2015 ... innovative bar flavors in 2014, Walgreens introduces the Cookies ... By focusing on innovation, Extend Nutrition has continually raised ... achieved a great taste, combined with an unprecedented nutritional ... Building on this success, Extend Nutrition will launch additional ...
(Date:5/5/2015)... LENEXA, Kan. (PRWEB) May 05, 2015 ... dedicated exclusively to healthcare providers, has been retained to ... Hospital in Helena, Mont. The top executive search firm ... placed more than 900 healthcare executives into organizations. , ... psychiatric treatment facility in Montana to offer both acute ...
Breaking Medicine News(10 mins):Health News:Live Streaming Fitness Creates Industry Shift by Bringing Fitness, Nutrition and Cooking Classes to Smart Devices 2Health News:Live Streaming Fitness Creates Industry Shift by Bringing Fitness, Nutrition and Cooking Classes to Smart Devices 3Health News:US Sports Camps, Nike Ultimate Camps, and Major League Ultimate Host Youth Ultimate Summer Camps in Philidelphia 2Health News:Igantia Announces Digital Initiative to Decode Longevity 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 3Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 4Health News:Shodair Children’s Hospital Retains B. E. Smith to Recruit New Administrator 2Health News:Shodair Children’s Hospital Retains B. E. Smith to Recruit New Administrator 3
... marketed as Revatio, study finds , TUESDAY, May 18 ... that causes progressive scarring of the lung tissue might ... Viagra, a new study finds. , The disease, called ... thick and stiff, reducing the ability to breathe. There,s ...
... life, study finds , TUESDAY, May 18 (HealthDay News) -- ... hurt feelings. Now, new research shows that a warm, caring ... growing up poor -- protection that can last well into ... with a higher risk for heart disease and other mental ...
... of the University of Helsinki, and Oncos Therapeutics, the ... next generation oncolytic viruses, published initial results from their ... The therapy program is based on scientific research at ... for ongoing clinical development. The results demonstrate ...
... the care they provide can vary widely depending upon the ... to a new RAND Corporation study. Researchers say the ... cost profiles that are being created by insurance companies in ... study provides more evidence that efforts to create physician cost ...
... will allow researchers to conduct larger, more effective studies ... in the United States. With a ... and Reinvestment Act of 2009, Cincinnati Children,s Hospital Medical ... (REGID). The first of its kind registry ...
... ... ever before. Get the facts on cancer and ways to prevent it from the Pulitzer ... ... the nation in the prevention and treatment of cancer. Truecancerfacts.com was written by Pulitzer Prize ...
Cached Medicine News:Health News:Viagra May Aid Those With Lung Fibrosis 2Health News:Viagra May Aid Those With Lung Fibrosis 3Health News:A Mother's Love Overcomes Poverty's Effect on Health 2Health News:A Mother's Love Overcomes Poverty's Effect on Health 3Health News:Oncolytic viruses mediating anti-tumor immunity in human cancer patients 2Health News:Results of physician cost profiling can vary widely, study finds 2Health News:National registry to track eosinophilic disorders 2Health News:What Doctors Won't Tell Their Patients About Cancer 2
(Date:5/5/2015)... , May 5, 2015 Lymphatic pump treatment ... antibiotic treatment, according to a new study published in ... Researchers performed LPT on infected rats ... a popular antibiotic used to treat pneumonia. After 96 ... free compared to only 25 percent of rats who ...
(Date:5/5/2015)... STATESVILLE, N.C. , May 5, 2015  Kewaunee Scientific ... Keith M. Gehl to Kewaunee Scientific,s Board of ... of Concord, North Carolina . ... Ross W. McCanless, notification to the Board of his ... due to his increased professional commitments. Upon his election, Mr. ...
(Date:5/5/2015)... 5, 2015 E-QURE (Electric Quick ... a premier provider of innovative medical devices in the ... update to shareholders and the investment community, covering 2014 ... of the proprietary Bioelectrical Signal Therapy™ (BST) Device for ... S-1, as well as its plans for commercialization and ...
Breaking Medicine Technology:Lymphatic Pump Treatment Enhances Antibiotic Effectiveness for Treating Pneumonia 2Keith M. Gehl Elected to Kewaunee Scientific Board of Directors 2Keith M. Gehl Elected to Kewaunee Scientific Board of Directors 3E-QURE Corp. Issues 2014 - 2015 Update to Shareholders 2E-QURE Corp. Issues 2014 - 2015 Update to Shareholders 3E-QURE Corp. Issues 2014 - 2015 Update to Shareholders 4E-QURE Corp. Issues 2014 - 2015 Update to Shareholders 5
... Presented at the World Muscle Society International ... PTC Therapeutics, Inc.,(PTC), a biopharmaceutical company ... small-molecule drugs targeting,post-transcriptional control mechanisms, today announced ... of PTC124 in patients with Duchenne muscular,dystrophy ...
... Access Pharmaceuticals, Inc.,(OTC Bulletin Board: ACCP) ... clinical and preclinical data on its lead ... the American Association for,Cancer Research (AACR), National ... and Treatment of Cancer (EORTC) entitled,"International Conference ...
Cached Medicine Technology:PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 2PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 3PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 4Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference 2
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
Hook design lifts and separates tissue for efficient dissection. Cautery action facilitates immediate control of bleeders....
This probe coagulates bleeders while suction channel with trumpet valve simultaneously evacuates smoke....
The control unit manage patient temperatures during long complex surgical procedures to help achieve optimal clinical outcomes....
Medicine Products: